中国生物制药5亿美金收购礼新医药,国际化战略再提速

医药魔方Info
15 Jul

先后牵手阿斯利康、默沙东,近三年对外授权总额近300亿元的“明星biotech”礼新医药,被港股制药龙头中国生物制药收入麾下!7月15日盘后,中国生物制药(01177.HK)公告,将以约5亿美元的总价收购上海礼新医药95.09%股权,加上此前参与礼新C轮融资时既已取得的4.91%股权,交易完成后,礼新医药将成为中国生物制药全资子公司。礼新医药主要研发和管理团队也将连同其备受关注的双抗、ADC等研发...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10